On the same day that it agreed a multi-billion-dollar deal to acquire endovascular treatment specialist ev3, Covidien also sealed a deal to divest its sleep therapy business. Yesterday, Covidien signed a definitive merger agreement worth $2.6bn which will see ev3 become a part of ...
Please Login to read the full article.
